SCHEMBL22456771

SCHEMBL22456771

CCN1CCCn2nccc2C1=O

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CACNA2D1 P54289 2/20 0.42
SLC6A2 P23975 1/20 0.42
POLB P06746 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
LMNA P02545 2/20 0.34
PER2 O15055 1/20 0.32
THRB P10828 1/20 0.32
TP53 P04637 3/20 0.31
KDM4E B2RXH2 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
IDE P14735 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
GAA P10253 1/20 0.31
PKN2 Q16513 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29349096 0.90 CACNA2D1 (0.35) CACNA2D1SLC6A2POLBSMN1; SMN2MEN1
SCHEMBL24127303 0.76 DRD2 (0.33)
SCHEMBL24026521 0.74 CACNA2D1 (0.36) CACNA2D1SLC6A2PER2
SCHEMBL24026520 0.74 CACNA2D1 (0.37) CACNA2D1SLC6A2SMN1; SMN2LMNAKDM4E
SCHEMBL24026711 0.72 CACNA2D1 (0.36) CACNA2D1SLC6A2LMNA
SCHEMBL24026719 0.70 CACNA2D1 (0.35) CACNA2D1SLC6A2SMN1; SMN2LMNAMEN1
SCHEMBL24026750 0.70 CACNA2D1 (0.35) CACNA2D1SLC6A2SMN1; SMN2LMNAMEN1
SCHEMBL17334313 0.67 CACNA2D1 (0.35) CACNA2D1SLC6A2POLBKDM4EMEN1
SCHEMBL20939379 0.67 HRH3 (0.34) CACNA2D1SLC6A2PER2
SCHEMBL9938226 0.66 GRM5 (0.41) CACNA2D1SLC6A2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200299297-A1 NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS ESTEVE PHARMACEUTICALS, S.A. (ES) 2020-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200299297-A1 NEW ALCOXYAMINO DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS CACNA1B, CACNB2, CACNA1G CACNA2D1 10/4885SLC6A2 28/4885POLB 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.